AZN

NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

Dollar change +1.04
Percentage change 1.52	%

Peers: ABBV PFE JNJ MRK NVS BMY GSK SNY LLY AMGN

| Held by: QQQ QQQM PVAL TQQQ FVD DIHP PPH DFIC AVDE QYLD

Scroll to Statements

Index	NDX	P/E	30.86	EPS (ttm)	2.25	Insider Own	0.02%	Shs Outstand	3.10B	Perf Week	3.73%
Market Cap	215.69B	Forward P/E	13.70	EPS next Y	5.08	Insider Trans	0.00%	Shs Float	3.10B	Perf Month	-4.79%
Income	7.04B	PEG	2.80	EPS next Q	1.12	Inst Own	16.79%	Short Float	0.34%	Perf Quarter	1.38%
Sales	54.07B	P/S	3.99	EPS this Y	9.35%	Inst Trans	-1.79%	Short Ratio	1.74	Perf Half Y	-10.19%
Book/sh	13.15	P/B	5.29	EPS next Y	13.11%	ROA	6.86%	Short Interest	10.60M	Perf Year	-0.83%
Cash/sh	1.82	P/C	38.15	EPS next 5Y	11.02%	ROE	17.60%	52W Range	61.24 - 87.68	Perf YTD	6.15%
Dividend Est.	1.61 (2.31%)	P/FCF	20.98	EPS past 5Y	34.63%	ROI	10.28%	52W High	-20.67%	Beta	0.42
Dividend TTM	1.55 (2.23%)	Quick Ratio	0.74	Sales past 5Y	17.77%	Gross Margin	72.23%	52W Low	13.57%	ATR (14)	1.90
Dividend Ex-Date	Feb 21, 2025	Current Ratio	0.93	EPS Y/Y TTM	18.11%	Oper. Margin	20.17%	RSI (14)	49.00	Volatility	1.81% 2.78%
Employees	94300	Debt/Eq	0.74	Sales Y/Y TTM	18.03%	Profit Margin	13.01%	Recom	1.38	Target Price	90.98
Option/Short	Yes / Yes	LT Debt/Eq	0.68	EPS Q/Q	56.16%	Payout	66.98%	Rel Volume	0.56	Prev Close	68.51
Sales Surprise	4.67%	EPS Surprise	0.97%	Sales Q/Q	23.84%	Earnings	Apr 29 BMO	Avg Volume	6.08M	Price	69.55
SMA20	0.85%	SMA50	-4.59%	SMA200	-5.75%	Trades		Volume	3,431,431	Change	1.52%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-15-25	Initiated	Exane BNP Paribas	Outperform	$75
Feb-13-25	Upgrade	UBS	Neutral → Buy
Feb-12-25	Initiated	Morgan Stanley	Overweight
Nov-20-24	Upgrade	UBS	Sell → Neutral
Nov-06-24	Upgrade	Deutsche Bank	Sell → Hold
Sep-13-24	Downgrade	Deutsche Bank	Hold → Sell
May-30-24	Initiated	Goldman	Buy	$97
Apr-16-24	Upgrade	Deutsche Bank	Sell → Hold
Feb-08-24	Downgrade	Deutsche Bank	Hold → Sell
Jan-23-24	Initiated	Morgan Stanley	Overweight	$85
Jan-16-24	Resumed	UBS	Sell
Jan-03-24	Downgrade	Jefferies	Buy → Hold	$78.50 → $70
Dec-18-23	Initiated	HSBC Securities	Buy	$78
Sep-25-23	Upgrade	Jefferies	Hold → Buy	$66.50 → $80
Jul-14-23	Initiated	HSBC Securities	Buy
Jul-12-23	Upgrade	UBS	Neutral → Buy
Jul-05-23	Downgrade	Deutsche Bank	Buy → Hold
Apr-11-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jan-05-23	Initiated	BMO Capital Markets	Outperform	$82
Sep-15-22	Downgrade	Credit Suisse	Outperform → Neutral

Show Previous Ratings

Today 05:00PM	STAAR Surgical Announces Changes to Board of Directors (Business Wire)
03:00PM	Tempus AI Stock Sees 21% Gain in 3 Days: Is it a Buy After AZN Deal? (Zacks)
02:20PM	Merck Q1 Earnings & Sales Beat Estimates, '25 EPS Outlook Cut (Zacks)
09:15AM	Unveiling Astrazeneca (AZN) Q1 Outlook: Wall Street Estimates for Key Metrics (Zacks)
07:59AM	Sanofi Q1 Earnings Top Estimates, Dupixent Drives Sales Growth (Zacks)
07:46AM	Loading…
07:46AM	Johnson & Johnson Just Proved The Bears Wrong Again (Seeking Alpha)
07:33AM	AstraZeneca enters $200m AI cancer pact with Tempus and Pathos (Pharmaceutical Technology)
06:53AM	Can Biogen Keep the Beat Streak Alive This Earnings Season? (Zacks)
Apr-23-25 12:04PM	AstraZeneca pushes EU to spend more on drugs amid Trump tariffs threat (The Telegraph)
08:00AM	Tempus Signs Expanded Strategic Agreements with AstraZeneca and Pathos to Develop the Largest Multimodal Foundation Model in Oncology (Business Wire)
05:51AM	Tectonic Therapeutic: A Buy On Massive Opportunity Of TX45 In PH HFpEF (Seeking Alpha)
Apr-22-25 06:15PM	Astrazeneca (AZN) Rises But Trails Market: What Investors Should Know (Zacks)
04:10PM	AstraZeneca rejoins leading U.S. drug lobby group after two-year absence (Reuters)
02:29PM	Regeneron to Report Q1 Earnings: What's in Store for the Stock? (Zacks)
09:00AM	Cellectis Charts Course for 2025 With Boost From AstraZeneca Deal (MarketBeat)
07:32AM	Loading…
07:32AM	Merck Q1 Earnings Coming Up: Should You Buy the Stock Now? (Zacks)
05:50AM	Daiichi and AstraZenecas Enhertu shows PFS benefits in breast cancer trial (Clinical Trials Arena)
Apr-21-25 05:02PM	Cellectis SA (CLLS) Q4 2024 Earnings Call Highlights: Strategic Collaborations and Financial ... (GuruFocus.com)
01:36PM	Novartis to Report Q1 Earnings: Will Key Drugs Maintain Momentum? (Zacks)
08:21AM	Should You Buy, Sell or Hold AstraZeneca Stock Before Q1 Earnings? (Zacks)
08:05AM	AstraZeneca- Daiichi Sankyo's Multi-Billion Dollar Cancer Drug Shows Superior Efficacy Across Broad HER2 Positive Metastatic Breast Cancer Patients (Benzinga)
07:00AM	ENHERTU (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival vs. THP as 1st-line therapy for patients with HER2+ metastatic breast cancer (Business Wire)
05:24AM	Enhertu combo tops standard drugs in first-line HER2 breast cancer (BioPharma Dive)
02:30AM	ENHERTU Plus Pertuzumab Demonstrated Highly Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival Versus THP as First-Line Therapy for Patients with HER2 Positive Metastatic Breast Cancer (Business Wire)
Apr-20-25 11:28AM	IDNA: The Cutting Edge Of Medical Science Is A Risky Investment (Seeking Alpha)
09:15AM	Selling America, Buying Europe - My Picks (Seeking Alpha)
Apr-18-25 04:46AM	89bio: A Buy With Strong Market Opportunity In MASH And SHTG (Seeking Alpha)
Apr-17-25 08:56PM	Lilly Soars As Study Shows Weight-Loss Pill to Pass Ozempic (Bloomberg)
Apr-16-25 09:45AM	Top Cancer Stocks to Buy to Boost Your Portfolio's Health (Zacks)
06:05AM	BGY: Underlying Fundamentals Can Be Improved (Seeking Alpha)
09:50PM	Loading…
Apr-15-25 09:50PM	Parnassus Value Select ETF Q1 2025 Commentary (Seeking Alpha)
02:51PM	Is AstraZeneca PLC (AZN) the Best Pharma Stock to Buy for Long Term Growth? (Insider Monkey)
05:39AM	Tariff wars to hit popular US-made drugs in China, regulator data shows (Reuters)
Apr-14-25 09:58AM	Is AstraZeneca (AZN) The Best UK Stock to Buy According to Billionaires? (Insider Monkey)
03:06AM	Nasdaq Bear Market: 3 Unstoppable Stocks You Can Buy With $300 Right Now (Motley Fool)
02:17AM	The Zacks Analyst Blog AbbVie's, Rinvoq and AstraZeneca's and Novartis (Zacks)
Apr-12-25 09:32AM	GRAIL's Galleri Progresses While Back In Accumulation Levels (Seeking Alpha)
Apr-11-25 01:20PM	Puma Biotechnology: Initiating Hold Rating With Limited Near-Term Upside And Uncertain Pipeline Potential (Seeking Alpha)
11:47AM	Pharma Stock Roundup: EU Nod to Expanded Use of ABBV, AZN Drugs & More (Zacks)
07:40AM	AstraZenecas oral breast cancer drug Truqap greenlit for NHS use (Pharmaceutical Technology)
Apr-10-25 08:54AM	Pharma Stocks Rebound as Trump Announces a 90-Day Pause on Tariffs (Zacks)
08:50AM	How to Find Strong Medical Stocks Slated for Positive Earnings Surprises (Zacks)
Apr-09-25 05:29PM	AbbVie: Thriving Beyond Humira's Patent Cliff (Upgrade) (Seeking Alpha)
12:03PM	Top Stock Movers Now: Delta, Apple, Eli Lilly, and More (Investopedia)
11:11AM	Why Roche Holding, Eli Lilly, and AstraZeneca Stocks Dropped Today (Motley Fool)
10:28AM	Pharma Stocks Sink as Trump Says 'Major' Tariffs Coming to Industry (Investopedia)
08:17AM	Novo Nordisk, AbbVie, Other Stocks Tumble After Trump Threatens Pharma Tariffs (The Wall Street Journal)
06:17AM	Pharma Stocks Drop After Trump Threatens Tariffs on Medicines (The Wall Street Journal)
05:40AM	Trump Says Pharmaceutical Tariffs Coming Very Shortly (Bloomberg)
05:10AM	3 No-Brainer Growth Stocks to Buy for Less Than $100 (Motley Fool)
Apr-08-25 06:15PM	Astrazeneca (AZN) Stock Moves -1.35%: What You Should Know (Zacks)
09:03AM	AstraZenecas camizestrant gains momentum, but questions remain as first-line therapy (Clinical Trials Arena)
Apr-07-25 07:40PM	Analyst Report: AstraZeneca PLC (Morningstar Research)
12:09PM	Thornburg International Growth Fund Q4 2024 Commentary (Seeking Alpha)
10:53AM	AZN Gets EU Nod for Expanded Use of Two Separate Cancer Drugs (Zacks)
06:37AM	EC approves AstraZenecas Imfinzi combo for NSCLC (Pharmaceutical Technology)
Apr-05-25 02:21AM	AstraZeneca's Innovation Ecosystem: From Blockbusters To The Next Generation Of Therapy (Seeking Alpha)
Apr-04-25 02:02PM	European Drug Regulator Approves AstraZeneca's Two Flagship Cancer Drugs For Breast And Lung Cancer Settings (Benzinga) -7.39%
10:41AM	Daiichi and AstraZenecas Enhertu gains EC approval for breast cancers (Pharmaceutical Technology)
09:46AM	Pharma Stock Roundup: FDA Nod to SNY, AZN & NVS, JNJ Talc Suits Failure (Zacks)
Apr-03-25 04:50PM	Why a Clutch of Pharmaceutical and Biotech Stocks Escaped the Market's Swoon on Thursday (Motley Fool)
03:15PM	Absci Corporation: A Potential Turnaround Play In Biotech Amid A Tumultuous Market (Seeking Alpha)
10:28AM	Spirits, Swiss Watches, Sneakers: Global Stock-Market Winners and Losers from Tariffs (The Wall Street Journal)
Apr-01-25 10:44PM	Q4 2024 AIM ImmunoTech Inc Earnings Call (Thomson Reuters StreetEvents)
02:34PM	Impax International Sustainable Economy Fund Q4 2024 Commentary (Seeking Alpha)
12:05PM	AstraZeneca says AZD0780 demonstrates significant LDL-C reduction in trial (TipRanks)
09:31AM	AstraZeneca's Imfinzi Gets FDA Nod for Bladder Cancer Indication (Zacks)
07:36AM	AstraZenecas AZD0780 cuts LDL-C by 50% in Phase IIb trial (Clinical Trials Arena)
04:27AM	FDA approves AstraZenecas Imfinzi combo for bladder cancer (Pharmaceutical Technology)
Mar-31-25 09:09PM	SPEU: A Solid Choice For Exposure To The Hot European Market (Seeking Alpha)
04:18PM	Does AstraZeneca Have 'One Pill To Rule Them All' In Cholesterol? (Investor's Business Daily)
02:36PM	FDA Approves AstraZeneca's Imfinzi As First Perioperative Immunotherapy For Muscle-Invasive Bladder Cancer Patients (Benzinga)
12:00PM	AZD0780, a novel oral PCSK9 inhibitor, demonstrated significant LDL cholesterol (LDL-C) reduction in PURSUIT Phase IIb trial (Business Wire)
09:45AM	PGIM Jennison Value Fund Q4 2024 Commentary (Seeking Alpha)
09:40AM	JNJ's Rybrevant-Lazcluze Combo Outshines AZN's Tagrisso in Lung Cancer (Zacks)
08:18AM	Stocks to Watch Monday: Nvidia, Tesla, Moderna, Stellantis (The Wall Street Journal)
07:00AM	IMFINZI (durvalumab) approved in the US as first and only perioperative immunotherapy for patients with muscle-invasive bladder cancer (Business Wire)
03:15AM	John Hancock International Growth Fund Q4 2024 Commentary (Seeking Alpha)
Mar-30-25 08:27AM	Hartford International Growth Fund Q4 2024 Commentary (Seeking Alpha)
05:00AM	Eli Lilly Vs. Novo Nordisk: Which Is The Better Bargain For Investors (Seeking Alpha)
Mar-29-25 12:06AM	PGIM Jennison Focused Value Fund Q4 2024 Commentary (Seeking Alpha)
Mar-28-25 11:55PM	PGIM Jennison Blend Fund Q4 2024 Commentary (Seeking Alpha)
05:23PM	Is AstraZeneca (AZN) the Best ADR Stock to Buy According to Hedge Funds? (Insider Monkey)
Mar-27-25 11:30AM	U.S. to end funding for child vaccines in developing countries, NY Times reports (TipRanks)
09:30AM	Brokers Suggest Investing in Astrazeneca (AZN): Read This Before Placing a Bet (Zacks)
08:31AM	IONS Out-Licenses ex-U.S. Rights for Rare Disease Drug Tryngolza to Sobi (Zacks)
08:30AM	Global Radiotherapy Market Expected to Reach $9.62 Billion By 2030 Realizing Growth Due to Technological Advancements (GlobeNewswire)
07:30AM	Franklin Biotechnology Discovery Fund Q4 2024 Commentary (SeekingAlpha)
03:27AM	How AZ and Amgens Tezspire respiratory data ups the level of ambition in immunology (Pharma Voice)
Mar-26-25 07:05PM	AstraZeneca says new results reinforce Tagrisso as backbone therapy (TipRanks)
06:15PM	Astrazeneca (AZN) Stock Moves -0.45%: What You Should Know (Zacks)
09:00AM	Lunit to Present AI Study on EGFR Mutation Prediction in NSCLC at AACR 2025 in Collaboration with AstraZeneca (PR Newswire)
08:17AM	Merck Inks $2B Licensing Deal With Chinese Biotech for Oral Heart Drug (Zacks)
Mar-25-25 07:02PM	New study results reinforce TAGRISSO (osimertinib) as the backbone therapy for EGFR-mutated lung cancer across stages and settings (Business Wire)
07:47AM	Fidelity Freedom Income Fund Q4 2024 Review (SeekingAlpha)
Mar-24-25 01:56PM	Argenx: The Magic May Be Already Priced In (SeekingAlpha)
01:12PM	Assemblin to upgrade AstraZenecas Gärtuna plant in Sweden (World Construction Network)
08:50AM	How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings (Zacks)
05:20AM	AstraZeneca to invest $2.5bn in R&D centre in China (Pharmaceutical Technology)
Mar-23-25 06:05AM	Forget the Correction: This Stock Is Defying the Sell-Off, and There Might Be More Upside Ahead (Motley Fool)

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Astrazeneca plc ADR

Upgrade your FINVIZ experience